REFERENCES
- Lesar T S. Comparison of ophthalmic β -blocking agents. Clin Pharm 1987; 6: 451–463, [PUBMED], [INFOTRIEVE]
- Nelson W L, Fraunfelder F T, Sills J M, Arrowsmith J B, Kuritsky J N. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. Am J Ophthalmol 1986; 102: 606–611, [PUBMED], [INFOTRIEVE]
- Akingbehin T, Raj P S. Ophthalmic topical beta blockers: review of ocular and systemic adverse effects. J Toxicol Cutaneous Ocul Toxicol 1990; 9: 131–147
- George M, Grass, Vincent H LL. A model to predict aqueous humor and plasma pharmacokinetics of ocularly applied drugs. Invest Ophthalmol Vis Sci 1993; 34: 2251–2259
- Vincent H LL, Joseph R R. Mechanistic and quantitavive evaluation of precorneal pilocalpine dispotition in albino rabbits. J Pharm Sci 1979; 68: 673–684
- Wada T, Toyoda Y, Takeuchi M, Oguma T, Ezure Y, Tsuriya Y, Suzuki N, Matsumoto Y, Kanagawa M, Ueda N, Azuma M. Precorneal resident of a newly developed reversible thermo-setting, in situ gelling ophthalmic vehicle of WP-934 (Rysmon® TG) [English translation]. Journal of the Eye (Atarasii Ganka) 1999; 16: 1311–1314
- In–house brochure of Rysmon® TG. Sagami Research Laboratories, Wakamoto Pharmaceutical Co., Ltd., Japan Jun., 2000, Experiment No.: GOT-9501
- Mishima S. Clinical pharmacokinetics of the eye. Invest Ophthalmol Vis Sci 1981; 21: 505–541
- Yamada Y, Takayanagi R, Tsuchiya K, Ito K, Ohtani H, Sawada Y, Iga T. Assessment of systemic adverse reactions induced by ophthalmic β -adrenergic receptor antagonists based on receptor occupancy. J Ocul Pharamacol Ther 2001; 17: 235–246, [CROSSREF]
- Hoshima F, Hashimoto T, Wada T, Nagasawa J, Tsuji S, Matsukawa H, Tsuriya Y, Maeda M, Kitazawa Y. Ocular hypotensive effect of WP-934 in rabbits [English translation]. Journal of the Eye (Atarasii Ganka) 1997; 14: 447–453
- Kitazawa Y, Tsukahara S, Azuma I, Abe H, Mishima H, Negi A, Nakashima M. Clinical evaluation of WP-934 ophthalmic solution in primary open-angle glucoma and ocular hypertension—phase 3 comparative study with timoptol® ophthalmic solution as control drug [English translation]. Journal of Clinical Therapeutics & Medicines (Rinshoiyaku) 1996; 12: 2683–2701
- Kitazawa Y, Tsukahara S, Abe H, Araie M, Nakashima M. Prolonged ocular hypotensive effect of WP-934 in primary open-angle glucoma and ocular hypertensive patients [English translation]. Journal of Clinical Therapeutics & Medicines (Rinshoiyaku) 1996; 12: 2703–2715
- Vuori M L, Kaila T. Plasma kinetics and antagonist activity of timolol in elderly patients. Graefes Arch Clin Exp Ophthalmol 1995; 223: 131–134, [CROSSREF]